Vor Biopharma Files 8-K: Rights Modifications & Other Events
Ticker: VOR · Form: 8-K · Filed: Sep 17, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Sep 17, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-action, filing
TL;DR
Vor Biopharma filed an 8-K today, expect news on security holder rights and other events.
AI Summary
On September 17, 2025, Vor Biopharma Inc. filed an 8-K report. The filing indicates material modifications to the rights of security holders and other events, along with financial statements and exhibits. The company is incorporated in Delaware and headquartered in Boston, Massachusetts.
Why It Matters
This 8-K filing signals potential changes affecting Vor Biopharma's security holders and may contain updates on significant company events or financial performance.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can impact stock price, and the nature of the modifications to security holder rights is not yet detailed.
Key Numbers
- 001-39979 — SEC File Number (Identifies the company's filing with the SEC.)
- 81-1591163 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- September 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Boston, Massachusetts (location) — Principal executive offices
- 001-39979 (identifier) — SEC File Number
FAQ
What specific material modifications were made to the rights of Vor Biopharma's security holders?
The filing indicates 'Material Modifications to Rights of Security Holders' as an item information, but the specific details of these modifications are not provided in the provided text.
What are the 'Other Events' reported by Vor Biopharma in this 8-K?
The filing lists 'Other Events' as an item information, but the specific nature of these events is not detailed in the provided text.
When was this 8-K filing submitted?
The filing was submitted on September 17, 2025.
Where is Vor Biopharma Inc. headquartered?
Vor Biopharma Inc.'s principal executive offices are located at 500 Boylston Street, Suite 1350, Boston, Massachusetts, 02116.
What is Vor Biopharma's Standard Industrial Classification (SIC) code?
Vor Biopharma Inc.'s SIC code is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,030 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-09-17 09:00:19
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
Filing Documents
- d945826d8k.htm (8-K) — 31KB
- d945826dex31.htm (EX-3.1) — 9KB
- 0001193125-25-205553.txt ( ) — 160KB
- vor-20250917.xsd (EX-101.SCH) — 3KB
- vor-20250917_lab.xml (EX-101.LAB) — 18KB
- vor-20250917_pre.xml (EX-101.PRE) — 11KB
- d945826d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Vor Biopharma Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 17, 2025 Vor Biopharma Inc. By: /s/ Jean-Paul Kress Name: Jean-Paul Kress Title: Chief Executive Officer